The neoadjuvant immune drug in this study was PD-1-inhibiting sindilizumab, which blocked the binding of PD-1 to PD-L1 and stimulated the activation of human immune cells, thus exerting cancer inhibition, and the neoadjuvant chemotherapeutic regimen was cisplatin + albumin paclitaxel, and the chemotherapy may have activated the tumor-specific T cells by facilitating the presentation of tumor antigens and destroying the immune-suppressing factors, which further enhanced the antitumor efficacy (31). The gene discussed is CD274; the disease is cancer.